The Latest Research on ALK+ Lung Cancer
What the Research Means for Patients
A lung cancer specialist and a long-term patient break down the most significant ALK+ treatment news of 2026 and what it means for your next oncologist appointment.
In this free program, Christine M. Lovly, MD, PhD, FASCO, Division Chief of Thoracic Medical Oncology at City of Hope Comprehensive Cancer Center, joins lung cancer patient advocate Jill Feldman to translate three major research updates from ASCO 2026 (the world’s largest cancer conference) into plain language, practical questions, and real answers. Experiences with ALK+ lung cancer vary, and this program is designed to help you understand what the latest evidence might mean and how to talk to your care team.
Program Topics
- Top Three Updates:
- CROWN trial 7-year data: Learn why researchers and oncologists are calling this the most significant ALK+ NSCLC result in years with more than half of patients on a specific targeted therapy had not seen their disease progress at seven years of follow-up, with the median still not reached
- LORIN Study: testing whether a specific targeted therapy given before surgery can shrink or eliminate stage III tumors
- ALKOVE-1: early data on an investigational new drug designed specifically for patients whose disease has progressed
- Plus:
- Get the full ALK+ treatment picture: Walk through how the three generations of ALK inhibitors differ, how oncologists now choose between them, and what happens if a first treatment stops working
- Know what to do about side effects on long-term therapy: Jill Feldman, who has been on targeted therapy for 15 years, talks honestly about what daily life looks like on long-term treatment
- Dose Reductions: Dr. Lovly explains why dose reductions (lowering your medication amount) are a real strategy, not a sign that treatment is failing.
Program Sponsor
Thank you to our sponsor for their support of our independent patient education program. The Patient Story retains full editorial control over all content.
